BioSpace News Archive

Amicus Therapeutics (Nasdaq: FOLD), today announced additional positive results from a global Phase 1/2 clinical study (ATB200-02) to investigate AT-GAA in adult patients with Pompe disease, an inherited lysosomal storage disorder caused by an enzyme deficiency that leads to accumulation of glycogen (disease substrate) in cells.

CareDx, Inc. announced that it will hold a virtual “Xenotransplantation Innovation Day” featuring a leading panel of transplant experts who will share the latest advancements in xenotransplantation after genetically modified pig kidneys and, separately, a pig heart were recently successfully transplanted, two medical firsts.

Todos Medical, Ltd. announced it has completed the acquisition of all 3CL protease biology-related assets and formed a majority-owned subsidiary called 3CL Pharma Ltd. 3CL Pharma will focus on developing therapeutics, diagnostics and dietary supplements based on 3CL protease biology related work of Dr. Dorit Arad, who joins Todos Medical as the newly appointed Chief Scientific Officer.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.

Karyopharm Therapeutics Inc. today announced that results from the Phase 3 SIENDO study will be presented at the European Society of Medical Oncology’s (ESMO) Virtual Plenary taking place on Thursday, March 17, 2022.

Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce’s advanced therapies drug development capabilities.

Grey Wolf Therapeutics today announced the appointment of Cassian Yee, M.D., to its clinical advisory board.

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) announced today earning a $25 million milestone payment from its collaboration with Janssen Biotech, Inc.

Glooko Inc. today announced the acquisition of DIABNEXT, a Paris-based company whose digital health platform helps people with diabetes better manage their conditions and connects to their healthcare providers, so they can work together to improve health outcomes.